The validation of findings through experimental approaches, such as western blot analysis in APP/PS1 transgenic mouse models, corroborates the potential of MAP4, GPT, and HIRIP3 as viable biomarkers and therapeutic targets for AD. Here, MAP4 is linked to Alzheimer disease.